CYSLTR1 and acute respiratory distress syndrome: Together with modest cysLTR1-mediated suppressive effects on neutrophils, the cysLTR1-independent anti-inflammatory activities of cysLTR1 antagonists are of potential therapeutic value in controlling harmful neutrophilic inflammation in many disorders including acute respiratory distress syndrome (ARDS) and systemic sepsis [134, 135].